BioCentury | Feb 15, 2020
Translation in Brief

COVID-19 therapy from Emory and diagnostic from Sherlock co-founders; plus Genentech, Homology and more

Emory, UNC to test nucleoside analog against COVID-19 The Emory Institute for Drug Development and University of North Carolina at Chapel Hill are conducting preclinical studies of nucleoside analog to treat COVID-19, an Emory University...
BioCentury | Feb 4, 2020
Finance

Co-founded by UPenn’s Wilson, Passage Bio outlines clinical goals in new IPO filing

Less than a year after emerging from stealth mode, gene therapy company Passage Bio revealed new details about its pipeline and clinical timelines through the filing of a prospectus for its planned IPO. Founded in...
BioCentury | Mar 29, 2019
Clinical News

Orchard planning MAA for leukodystrophy stem cell gene therapy

Orchard plans to submit an MAA to EMA in 2020 for OTL-200 to treat metachromatic leukodystrophy after reporting that the therapy met a co-primary endpoint of improving motor function at two years following treatment in...
BioCentury | May 11, 2018
Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...
BioCentury | Mar 31, 2018
Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
BioCentury | Jul 21, 2014
Strategy

AbbVie's plan B

Clinical setbacks and a rapidly evolving HCV landscape have left AbbVie Inc. less insulated from potential biosimilar competition for blockbuster Humira adalimumab. Now that Shire plc has decided to accept AbbVie's takeout bid, the specialty...
BioCentury | Nov 18, 2013
Strategy

Shire goes vertical

The proposed $4.2 billion buyout of ViroPharma Inc. fits Shire plc 's long-standing growth through acquisition model, but the new CEO also wants to focus on internal R&D in rare diseases. This deal is an...
BioCentury | Aug 5, 2013
Clinical News

Autologous CD34+ cells: Phase I/II data

The open-label, Italian Phase I/II TIGET-MLD trial in 3 evaluable pre-symptomatic patients with evidence of late infantile MLD showed that IV infusions of autologous CD34+ cells transfected with a lentiviral vector encoding functional ARSA protein...
BioCentury | May 20, 2013
Strategy

Let a thousand ideas bloom

Shire plc has long been a growth through acquisition company, but the pace of its external discovery is picking up steam and the company now has over 20 ongoing projects to show for it. Traditional...
BioCentury | Dec 24, 2012
Product Development

Shire homes in

Proof-of-concept data in cancer for Arrowhead Research Corp. 's peptide-based tissue targeting platform were good enough to get Shire plc on board to use the technology for rare diseases. Last week, the companies partnered to...
Items per page:
1 - 10 of 26